Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020
Author(s) -
Fiona P. Havers,
Carrie Reed,
Travis Lim,
Joel M. Montgomery,
John D. Klena,
Aron J. Hall,
Alicia M. Fry,
Deborah Can,
ChengFeng Chiang,
Aridth Gibbons,
Inna Krapiunaya,
Maria Morales-Betoulle,
Katherine Roguski,
Mohammad Rasheed,
Brandi Freeman,
Sandra Lester,
Lisa A. Mills,
Darin S. Carroll,
S. Michele Owen,
Jeffrey A. Johnson,
Vera Semenova,
Carina Blackmore,
Debra Blog,
Shua J. Chai,
Angela Dunn,
Julie Hand,
Seema Jain,
Scott Lindquist,
Ruth Lynfield,
Scott Pritchard,
Theresa Sokol,
Lynn Sosa,
George Turabelidze,
Sharon Watkins,
John Wiesman,
Randall Williams,
Stephanie Yendell,
Jarad Schiffer,
Natalie J. Thornburg
Publication year - 2020
Publication title -
jama internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.14
H-Index - 342
eISSN - 2168-6114
pISSN - 2168-6106
DOI - 10.1001/jamainternmed.2020.4130
Subject(s) - seroprevalence , medicine , serology , population , bay , demography , covid-19 , antibody , veterinary medicine , disease , immunology , environmental health , infectious disease (medical specialty) , geography , archaeology , sociology
Reported cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection likely underestimate the prevalence of infection in affected communities. Large-scale seroprevalence studies provide better estimates of the proportion of the population previously infected.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom